Berman David M, an insider at Immunocore Holdings PLC (IMCR), purchased 100 shares of the company's stock on November 23, 2025, at a price of $17.46 per share, totaling $2,000. Following this transaction, Berman holds 100 shares of Immunocore.
Immunocore operates as a commercial-stage biotechnology company, focusing on developing TCR bispecific immunotherapies, known as ImmTAX. The firm is headquartered in Abingdon, Oxfordshire, and employs 493 full-time staff. It went public on February 5, 2021, and currently has a market capitalization of $1.8 billion. The company’s lead product, KIMMTRAK, targets patients with unresectable or metastatic uveal melanoma (mUM), and its pipeline includes several clinical-stage programs across various cancers.
Insider transactions, such as this purchase, are reported to the SEC and can serve as a transparency measure regarding executives' perspectives on their company's stock. However, investors should consider these transactions as part of broader patterns rather than isolated events. Upcoming earnings for Immunocore are scheduled for May 5, 2026, with an estimated EPS of -$0.19 and revenue of $112.5 million, followed by another report on August 5, 2026, projecting an EPS of -$0.23 and revenue of $114.6 million.